Tenaya Therapeutics, Inc. (TNYA)
0.6993
+0.01
(+2.03%)
USD |
NASDAQ |
Sep 02, 16:00
0.6951
0.00 (0.00%)
Pre-Market: 08:44
Tenaya Therapeutics Research and Development Expense (TTM) : 61.61M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 61.61M |
| March 31, 2026 | 62.37M |
| December 31, 2025 | 68.61M |
| September 30, 2025 | 72.50M |
| June 30, 2025 | 77.48M |
| March 31, 2025 | 82.76M |
| December 31, 2024 | 86.74M |
| September 30, 2024 | 90.92M |
| June 30, 2024 | 93.66M |
| March 31, 2024 | 97.49M |
| December 31, 2023 | 98.04M |
| September 30, 2023 | 100.92M |
| Date | Value |
|---|---|
| June 30, 2023 | 101.59M |
| March 31, 2023 | 95.99M |
| December 31, 2022 | 94.54M |
| September 30, 2022 | 89.74M |
| June 30, 2022 | 78.93M |
| March 31, 2022 | 68.96M |
| December 31, 2021 | 54.39M |
| September 30, 2021 | 41.80M |
| June 30, 2021 | 37.34M |
| March 31, 2021 | 33.39M |
| December 31, 2020 | 31.10M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Intellia Therapeutics, Inc. | 337.63M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |
| Sangamo Therapeutics, Inc. | 113.79M |
| Sarepta Therapeutics, Inc. | 783.60M |